Show simple item record

dc.contributor.authorVarghese, Robin T.en
dc.contributor.authorLiang, Yanpingen
dc.contributor.authorGuan, Tingen
dc.contributor.authorFranck, Christopher T.en
dc.contributor.authorKelly, Deborah F.en
dc.contributor.authorSheng, Zhien
dc.date.accessioned2017-03-24T18:52:20Zen
dc.date.available2017-03-24T18:52:20Zen
dc.date.issued2016-04-12en
dc.identifier.issn1949-2553en
dc.identifier.urihttp://hdl.handle.net/10919/76674en
dc.description.abstractCancer biomarkers with a strong predictive power for diagnosis/prognosis and a potential to be therapeutic targets have not yet been fully established. Here we employed a loss-of-function screen in glioblastoma (GBM), an infiltrative brain tumor with a dismal prognosis, and identified 20 survival kinase genes (SKGs). Survival analyses using The Cancer Genome Atlas (TCGA) datasets revealed that the expression of CDCP1, CDKL5, CSNK1E, IRAK3, LATS2, PRKAA1, STK3, TBRG4, and ULK4 stratified GBM prognosis with or without temozolomide (TMZ) treatment as a covariate. For the first time, we found that GBM patients with a high level of NEK9 and PIK3CB had a greater chance of having recurrent tumors. The expression of CDCP1, IGF2R, IRAK3, LATS2, PIK3CB, ULK4, or VRK1 in primary GBM tumors was associated with recurrence-related prognosis. Notably, the level of PIK3CB in recurrent tumors was much higher than that in newly diagnosed ones. Congruent with these results, genes in the PI3K/AKT pathway showed a significantly strong correlation with recurrence rate, further highlighting the pivotal role of PIK3CB in the disease progression. Importantly, 17 SKGs together presented a novel GBM prognostic signature. SKGs identified herein are associated with recurrence rate and present prognostic significance in GBM, thereby becoming attractive therapeutic targets.en
dc.format.extent20140 - 20151 (12) page(s)en
dc.languageEnglishen
dc.publisherImpact Journals Llcen
dc.relation.urihttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000375804000079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=930d57c9ac61a043676db62af60056c1en
dc.rightsCreative Commons Attribution 3.0 Unporteden
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/en
dc.subjectOncologyen
dc.subjectCell Biologyen
dc.subjectsurvival kinase genesen
dc.subjectglioblastomaen
dc.subjecttumor recurrenceen
dc.subjectprognosisen
dc.subjectPIK3CBen
dc.subjectMGMT PROMOTER METHYLATIONen
dc.subjectSTEM-LIKE CELLSen
dc.subjectVIVO RNAI SCREENen
dc.subjectRECURRENT GLIOBLASTOMAen
dc.subjectMALIGNANT GLIOMAen
dc.subjectKEY REGULATORen
dc.subjectTEMOZOLOMIDEen
dc.subjectMULTIFORMEen
dc.subjectPROTEINen
dc.subjectTUMORSen
dc.titleSurvival kinase genes present prognostic significance in glioblastomaen
dc.typeArticle - Refereeden
dc.description.versionPublished (Publication status)en
dc.title.serialONCOTARGETen
dc.identifier.volume7en
dc.identifier.issue15en
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/Scienceen
pubs.organisational-group/Virginia Tech/Science/COS T&R Facultyen
pubs.organisational-group/Virginia Tech/Science/Statisticsen
pubs.organisational-group/Virginia Tech/University Research Institutesen
pubs.organisational-group/Virginia Tech/University Research Institutes/Virginia Tech Carilion Research Instituteen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 3.0 Unported
License: Creative Commons Attribution 3.0 Unported